RxDoctor Payments Data

Dennis Reedy, MD

Gastroenterology · East Syracuse, NYNPI 1285614404

Payments from drug & device makers

$2,161in general payments, 2019–2025

Across 58 payments — averaging $37.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$576
  • Gilead$309
  • Cook Medical LLC$286
  • Steris Corporation$142
  • Janssen Scientific Affairs, LLC$125
  • Ferring Pharmaceuticals Inc.$125
  • plus $598 from 14 others

What the payments were for

  • Food & beverage$2,13899%
  • Education$221%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,161 in reported general payments places this provider in the 50th percentile of 1,682 gastroenterology providers in New York.

See all gastroenterology providers in New York

Medicare billing

Part B allowed, 2024
$121,752
Medicare patients
516
Services billed
804

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab13$356,754
Humira(Cf) PenAdalimumab26$257,649
CreonLipase/Protease/Amylase26$50,378
XifaxanRifaximin21$39,953
LinzessLinaclotide35$38,850
SutabSod Sulf/Pot Chloride/Mag Sulf82$12,875
Mesalamine22$10,547
Chlordiazepoxide-ClidiniumChlordiazepoxide/Clidinium Br13$9,934
Dexlansoprazole DrDexlansoprazole20$6,205
Ursodiol22$4,948
Omeprazole267$4,737
Lubiprostone11$3,403
Colestipol Hcl23$3,182
Famotidine122$2,293
Sucralfate20$1,714

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon, Linzess$576$89,22861 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 1,682 gastroenterology providers in New York.

Other gastroenterology in East Syracuse

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →